Heartflow NASDAQ: HTFL reported a sharply higher first-quarter revenue total and raised its full-year 2026 outlook, citing strength in its core FFRCT business, faster-than-expected adoption of its Plaque Analysis product and continued expansion of the coronary CT angiography, or CCTA, market.
HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript
HeartFlow delivered 40% sales growth in 2025, with revenue surpassing $176 million and strong Q4 momentum. 2026 guidance targets 25% revenue growth to $218–222 million, with gross margins rising to 80–81% and further mid-term upside to 85%. HearthFlow's AI-driven CAD diagnostic platform is gaining adoption, supported by FDA-cleared next-generation algorithms and a proprietary CT image database.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Point72 Asset Management LP Point72 Asset Management LP | 538,351 | $15.47M | $16.51M | $1.04M | 6.73% |
| JC Joseph Castro Nuveen LLC | 23,239 | $677,417 | $712,507.74 | $35,090.74 | 5.18% |
| TC Thomas Cagna Sandia Investment Management LP | 15,917 | $497,805.55 | $488,174.39 | -$9,631.16 | -1.93% |
| BB Brian Baylis Bell Investment Advisors Inc. | 70 | $2,040.5 | $2,146.9 | $106.4 | 5.21% |
| RO Regan O'Neill Burkehill Global Management LP | 65,000 | $2.19M | $2M | -$185,250 | -8.47% |
| Health Care Technology Industry | Healthcare Sector | John Farquhar CEO | NASDAQ (NMS) Exchange | 42238D107 CUSIP |
| US Country | 626 Employees | - Last Dividend | - Last Split | - IPO Date |